Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-11-02
1993-12-28
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514396, 514399, 514815, A61K 31415
Patent
active
052739929
ABSTRACT:
The present invention provides a chemical class of active compounds to be used as efficacious drugs in the treatment of sickle cell disease. The active compounds include imidazole derivatives, nitroimidazole derivatives, and triazole derivatives. These compounds are to be administered by any preferred route of administration including oral, intramuscular, intravenous, and any other parenteral route. If desired, these drugs may also be administered transmucosally, or subcutaneously, or using a dermal patch on the skin. In addition, the methodology is effective for both long term and short term therapy; may be employed prophylactically and/or therapeutically; and may be used in emergency, acute crisis clinical situations.
REFERENCES:
patent: 4343808 (1982-08-01), Broersma, Jr. et al.
patent: 4696937 (1987-09-01), Sebille et al.
Swamy et al., Chem. Abstracts CA85(9):56689d, 1976.
Chang et al., Medline 83244512(NLM), May 1983.
Alper Seth L.
Brugnara Carlo
Beth Israel Hospital Assoc. Inc.
Friedman S. J.
Jarvis William
Prashker David
LandOfFree
Method for reducing sickle erythrocyte dehydration and delaying does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing sickle erythrocyte dehydration and delaying , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing sickle erythrocyte dehydration and delaying will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1542897